Rovelizumab has not been previously associated with DMD; however, we show that it is able to modulate two predicted candidate genes (ITGB2, ITGAM) that are associated with DMD in mdx mice [42,43]. This evidence concerns the gene ITGB2 and Duchenne muscular dystrophy.